Australia's Radiopharm Theranostics rises on partnership with Lantheus

Radiopharm Theranostics

30/12/2024 24:33

** Shares of clinical-stage biopharmaceutical firm
Radiopharm Theranostics  RAD.AX  rise as much as 21.7% to
A$0.028, their highest since Dec. 16
    ** Co inks co-development deal to develop biopharmaceuticals
with Massachusetts-based Lantheus  LNTH.O  in Australia
    ** Deal includes basket clinical trial targeting multiple
solid tumours
    ** Co to receive up to $2 mln in milestone payments upon
achieving key objectives, with the LNTH footing all costs
    ** Including session's moves, stock trims YTD losses to
64.9% as of 2340 GMT

 (Reporting by Kumar Tanishk in Bengaluru)
 ((Tanishk.Kumar@thomsonreuters.com;))